| Bioactivity | SPT-IN-1 (compound 1) is an orally active and potent SPT (serine palmitoyl transferase) inhibitor, with an IC50 of 5.19 nM for hSPT1. SPT-IN-1 can be used for type 2 diabetes and dyslipidemia research[1]. |
| Target | IC50: 5.19 nM (hSPT1) |
| Invitro | SPT-IN-1 (compound 1) exhibits a dose-dependent inhibition of C14-serine incorporation into ceramide in MCF-7 cells, with EC50 of 0.98 μM[1]. |
| In Vivo | SPT-IN-1 (compound 1) (Sprague Dawley rats, 0-60 mg/kg, Orally, twice daily for 7 days) dose-dependently reduces plasma ceramides, reduces triglycerides and raises HDL in cholesterol/cholic acid fed rats[1]. |
| Name | SPT-IN-1 |
| CAS | 1933533-18-6 |
| Formula | C22H24N2O3 |
| Molar Mass | 364.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Genin MJ, et al. Imidazopyridine and Pyrazolopiperidine Derivatives as Novel Inhibitors of Serine Palmitoyl Transferase. J Med Chem. 2016;59(12):5904-5910. |